Current FDA-approved therapies consist exclusively of oral Janus kinase (JAK) inhibitors, which are restricted to severe cases and require systemic immunosuppression that carries boxed warnings for serious infections, malignancies, and cardiovascular events.
Cinainu represents the first multi-plant botanical drug candidate to receive FDA Breakthrough Therapy status. Formulated from standardized extracts of four botanical sources, the topical solution works through multi-target immunomodulation, interleukin-8 (IL-8) suppression, and follicular microenvironment remodeling without shutting down the systemic immune system. In published Phase 2/3 clinical trial results in the British Journal of Dermatology, Cinainu demonstrated significant hair regrowth that continued to widen over placebo even after treatment was stopped, showing sustained immune remission with zero systemic immunosuppressive toxicity.
What Is It and How Does It Work?
The therapeutic mechanism centers on Topical Multi-Target Immunomodulation, Interleukin-8 Chemokine Neutralization, and Follicular Collagen Matrix Support—restoring local immune tolerance and shielding hair roots without whole-body immune suppression.
-
The Problem with Systemic Immunosuppression: Alopecia areata is driven by an autoimmune collapse of the hair follicle’s “immune privilege” sanctuary. Cytotoxic T cells infiltrate the follicle bulb, releasing cytokines like interferon-gamma (IFN-$\gamma$) and interleukin-15 (IL-15) that halt hair synthesis. While oral JAK inhibitors block these downstream cytokine cascades, they do so by dampening immune pathways throughout the entire body, creating long-term safety concerns—especially in pediatric patients.
-
The Multi-Plant Botanical Matrix: Cinainu (investigational code LH-8) is a standardized, regulated topical formulation composed of four active botanical extracts: Allium cepa (onion), Citrus limon (lemon), Paullinia cupana (guarana), and Theobroma cacao (cocoa). Unlike single-molecule synthetic compounds, the combined phytochemicals interact simultaneously across multiple inflammatory and cellular targets.
-
Neutralizing Interleukin-8 (IL-8/CXCL8): A key driver of hair follicle immune privilege collapse is the chemokine IL-8, which acts as a homing beacon to recruit inflammatory cells to the outer root sheath. Cinainu’s active flavonoids and polyphenols directly suppress local IL-8 expression and dampen JAK-dependent signaling cascades, preventing inflammatory immune cells from gathering around the follicle bulb.
-
Preventing Hair Matrix Apoptosis: The formulation exerts direct anti-apoptotic and antioxidant effects on dermal papilla cells and hair matrix keratinocytes, protecting them from oxidative stress and cell death.
-
Remodeling the Dermal Microenvironment: Beyond calming inflammation, Cinainu increases scalp collagen synthesis and supports microvascular endothelial activation, strengthening the extracellular matrix around hair roots to maintain anagen cycling.
The Science: Clear Results from the RAAINBOW Phase 2/3 Trial
The international, double-blind, randomized, placebo-controlled RAAINBOW trial evaluated 107 pediatric and adolescent patients (aged 2 to 17 years) presenting with active alopecia areata involving 25% to 95% scalp hair loss. Patients applied either Cinainu or a placebo vehicle topically for 24 weeks, followed by a 24-week untreated monitoring period:
-
Statistically Superior Regrowth at Week 24: In the primary analysis population, patients treated with Cinainu achieved an average of 26 percent more hair regrowth compared to the placebo group by Week 24. More than 1 in 4 treated patients achieved noticeable clinical improvement, compared to just 1 in 20 in the placebo arm.
-
Widening Benefits After Stopping Treatment: During the 24-week untreated follow-up period, the difference between Cinainu and placebo widened further, reaching a 39.4 percent advantage at Week 48 ($p = 0.003$; Cohen’s $d = 0.80$). This confirms that the topical solution induced a durable reset in local immune tolerance rather than a temporary suppression that relapses immediately upon cessation.
-
Meaningful Quality-of-Life Gains: Standardized assessments showed substantial improvements in patient wellbeing, with clinically meaningful effect sizes on the Children’s Dermatology Life Quality Index (CDLQI, effect size 0.61) and EuroQol Visual Analogue Scale (EQ-VAS, effect size 0.69).
-
Absence of Systemic Toxicities: Unlike oral immunosuppressants, Cinainu demonstrated a safety profile comparable to placebo. No serious drug-related adverse events occurred, and side effects were limited to mild, transient application-site reactions.
“The between-group difference grew during the untreated follow-up, reaching 39.4% at week 48… Cinainu led to better hair regrowth compared with placebo… These results suggest that Cinainu could offer a safe and effective new treatment option for children with moderate-to-severe AA, helping to fill an important gap in current care.”— Dr. Ulrike Blume-Peytavi, MD, and International Research Consortium, British Journal of Dermatology.
When Will It Be Available?
-
Current Stage: Completed randomized Phase 2/3 trial in children and adolescents (RAAINBOW); granted US FDA Breakthrough Therapy Designation in October 2026 for adults and children aged 2 and older.
-
Timeline: With FDA clearance of its Investigational New Drug (IND) application, Legacy Healthcare is preparing a global pivotal Phase 3 program (RAAINBOW-2) evaluating adults, adolescents, and young children. Because Breakthrough Therapy status expedites regulatory guidance and review timelines, commercial prescription approval is projected between 2028 and 2029.
How you can benefit from this treatment now
-
The Shift to Immune-Sparing Topicals: This regulatory breakthrough demonstrates that treating autoimmune hair loss does not necessarily require lifelong whole-body immunosuppression with oral pills. In the future, patients with patchy or moderate alopecia areata will have access to non-toxic topical solutions that reset local immune balance without infection risks.
-
Identify Patchy vs Pattern Loss Early: Alopecia areata typically presents as rapid, smooth, circular patches of shedding, distinct from gradual receding at the temples and crown seen in genetic pattern baldness. If you or a family member notice sudden circular patches, consult a board-certified dermatologist promptly to assess follicular inflammation and confirm an autoimmune diagnosis.
-
Manage Scalp Surface Micro-Inflammation: Because interleukin-8 and localized oxidative stress accelerate hair follicle immune privilege collapse, keeping the scalp environment calm is essential. Using gentle, physiological-pH shampoos and anti-inflammatory topical washes containing green tea extract (EGCG) or zinc pyrithione helps reduce surface oxidative stress.
-
Support Systemic Immune Regulation Naturally: Adequate vitamin D levels are essential for normal immune tolerance and regulatory T-cell activity. Speak with your physician about checking your 25-hydroxyvitamin D levels, as correcting a deficiency provides baseline support for hair follicle immune privilege.
-
Do Not Mix DIY Kitchen Extracts: Although Cinainu is derived from onion, lemon, guarana, and cacao, applying raw household extracts or kitchen juices to an inflamed scalp is ineffective and risky. Raw juices contain acidic compounds, allergens, and unstandardized irritants that can cause severe contact dermatitis, accelerating follicle shedding rather than delivering the stabilized, micro-purified phytochemical concentrations used in clinical trials.
Action: If you or a family member notice sudden, circular patches of hair loss, schedule an in-person dermoscopic evaluation with a dermatologist to verify whether local immune privilege has broken down and determine if targeted anti-inflammatory or clinical-trial options are appropriate.